Previous 10 | Next 10 |
home / stock / agnpf / agnpf news
VANCOUVER, British Columbia, Jan. 11, 2024 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) a Canadian clinical stage pharmaceutical development company is pleased to announce that it has r...
2023-12-27 07:50:16 ET More on Algernon Pharmaceuticals Algernon Pharmaceuticals announces private placement Seyltx acquires Algernon's chronic cough research program for $2M and 20% stake Financial information for Algernon Pharmaceuticals For further details...
VANCOUVER, British Columbia, Dec. 27, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) (the “ Company ” or “ Algernon ”) a Canadian clinical stage pharmaceutical development company announces an increase to...
2023-12-13 02:57:04 ET More on Algernon Pharmaceuticals Seyltx acquires Algernon's chronic cough research program for $2M and 20% stake Financial information for Algernon Pharmaceuticals For further details see: Algernon Pharmaceuticals announces private placement
VANCOUVER, British Columbia, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) a Canadian clinical stage pharmaceutical development company, is pleased to announce that it has recei...
2023-11-22 07:35:34 ET More on Algernon Pharmaceuticals Financial information for Algernon Pharmaceuticals For further details see: Seyltx acquires Algernon's Chronic Cough Research Program for $2M and 20% stake
VANCOUVER, British Columbia, Nov. 22, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage pharmaceutical development company, is pleased to announce that it has...
2023-11-08 07:18:52 ET More on Algernon Pharmaceuticals Financial information for Algernon Pharmaceuticals For further details see: Algernon gets Japanese patent notice of allowance for treatment of NASH with Repirinast
VANCOUVER, British Columbia, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) a clinical stage pharmaceutical development company is pleased to announce that it has received a...
VANCOUVER, British Columbia, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a clinical stage pharmaceutical development company, is pleased to announce that it has been is...
News, Short Squeeze, Breakout and More Instantly...
Algernon Pharmaceuticals Inc - Class A Company Name:
AGNPF Stock Symbol:
OTCMKTS Market:
VANCOUVER, British Columbia, April 24, 2024 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the "Company" or "AGN Pharma") (CSE:AGN) (FRANKF...
VANCOUVER, British Columbia, April 24, 2024 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “AGN Pharma”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage pharmaceutical development company, is pleased to announce that its...
VANCOUVER, British Columbia, April 11, 2024 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the "Company" or "Algernon") (CSE:AGN) (FRANKFUR...